Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827462 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL1985823 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL2175496 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL2177991 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL2174526 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL132521 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL2173439 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL536857 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL443449 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL294141 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5352689-A | Rhizoxin derivatives and their use as anti-tumor agents | SANKYO COMPANY, LIMITED (JP) | 1994-10-04 | — | — | US | claimed |
| EP-2653498-B1 | POLYBUTYLENE TEREPHTHALATE RESIN COMPOSITION AND PELLET THEREOF | WINTECH POLYMER LTD (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-9790344-B2 | Polybutylene terephthalate resin composition and pellet thereof | WINTECH POLYMER LTD. (JP) | 2017-10-17 | — | — | US | disclosed |
| US-20130309500-A1 | POLYBUTYLENE TEREPHTHALATE RESIN COMPOSITION AND PELLET THEREOF | WIN TECH POLYMER LTD. (JP) | 2013-11-21 | — | — | US | disclosed |
| EP-2653498-A1 | POLYBUTYLENE TEREPHTHALATE RESIN COMPOSITION AND PELLET THEREOF | Wintech Polymer Ltd. (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-7973145-B2 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100298246-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20090209475-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-5391564-A | E.g., rhizoxin-13-yl 3-methylthiopropionate; anticarcinogenic agents | SANKYO COMPANY, LIMITED (JP) | 1995-02-21 | — | — | US | disclosed |
| US-5352689-A | Rhizoxin derivatives and their use as anti-tumor agents | SANKYO COMPANY, LIMITED (JP) | 1994-10-04 | — | — | US | disclosed |
| EP-0350315-B1 | RHIZOXIN DERIVATES AND THEIR USE AS ANTI-TUMOR AGENTS | SANKYO COMPANY LIMITED (JP) | 1993-06-16 | — | — | EP | disclosed |
| EP-0350315-A1 | Rhizoxin derivates and their use as anti-tumor agents | SANKYO COMPANY LIMITED (JP) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298246-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | SLC5A2, SLC5A1, DEGS1 | LMNA 3304/4885KDM4C 2335/4885TRPV1 1543/4885 |
| US-20090209475-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | SLC5A2, SLC5A1, DEGS1 | LMNA 3304/4885KDM4C 2335/4885TRPV1 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.